H.C. Wainwright analyst Brandon Folkes initiated coverage of Journey Medical (DERM) with a Buy rating and $13 price target The firm believes the company’s Emrosi has demonstrated clinical superiority to market leader Oracea in rosacea. This creates the potential for prescription demand and revenue pull through to exceed current consensus expectations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: